Phase III X-TOLE2 data support azetukalner filing in focal onset seizures
Xenon Pharmaceuticals reported positive Phase III X-TOLE2 results for azetukalner in focal onset seizures. The company plans an FDA new drug application in Q3 2026.
Also known as: Kv7, KV7
Xenon Pharmaceuticals reported positive Phase III X-TOLE2 results for azetukalner in focal onset seizures. The company plans an FDA new drug application in Q3 2026.
Xenon Pharmaceuticals will announce topline data from its Phase 3 X-TOLE2 study of azetukalner in patients with focal onset seizures on March 9, 2026, during a conference call at 8:00 a.m. ET.
Drug Hunter's monthly molecule selections from July through December 2025 feature innovative small molecule candidates targeting pain, epilepsy, cancer, infectious diseases, and metabolic disorders, including non-opioid pain agents and precision therapies for rare conditions.